$33.09
1.58% yesterday
Nasdaq, Aug 25, 10:05 pm CET

Omnicell, Inc. Stock price

$33.09
+4.82 17.05% 1M
-6.39 16.19% 6M
-11.43 25.67% YTD
-12.34 27.16% 1Y
-77.96 70.20% 3Y
-35.36 51.66% 5Y
-0.62 1.84% 10Y
+24.45 282.99% 20Y
Nasdaq, Closing price Mon, Aug 25 2025
-0.53 1.58%

Key metrics

Basic
Market capitalization
$1.5b
Enterprise Value
$1.4b
Net debt
positive
Cash
$425.0m
Shares outstanding
46.4m
Valuation (TTM | estimate)
P/E
67.5 | 20.9
P/S
1.3 | 1.3
EV/Sales
1.3 | 1.2
EV/FCF
16.1
P/B
1.2
Financial Health
Equity Ratio
58.6%
Return on Equity
1.0%
ROCE
1.0%
ROIC
0.7%
Debt/Equity
0.3
Financials (TTM | estimate)
Revenue
$1.1b | $1.2b
EBITDA
$102.7m | $136.9m
EBIT
$15.5m | $78.0m
Net Income
$23.1m | $73.4m
Free Cash Flow
$89.2m
Growth (TTM | estimate)
Revenue
6.4% | 5.4%
EBITDA
61.6% | 43.7%
EBIT
160.3% | 1,320.6%
Net Income
211.4% | 485.7%
Free Cash Flow
-41.2%
Margin (TTM | estimate)
Gross
43.9%
EBITDA
8.9% | 11.7%
EBIT
1.3%
Net
2.0% | 6.3%
Free Cash Flow
7.8%
More
EPS
$0.5
FCF per Share
$1.9
Short interest
6.4%
Employees
4k
Rev per Employee
$300.0k
Show more

Is Omnicell, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Omnicell, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Omnicell, Inc. forecast:

10x Buy
71%
4x Hold
29%

Analyst Opinions

14 Analysts have issued a Omnicell, Inc. forecast:

Buy
71%
Hold
29%

Financial data from Omnicell, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
1,150 1,150
6% 6%
100%
- Direct Costs 645 645
2% 2%
56%
504 504
12% 12%
44%
- Selling and Administrative Expenses 398 398
3% 3%
35%
- Research and Development Expense 89 89
1% 1%
8%
103 103
62% 62%
9%
- Depreciation and Amortization 87 87
2% 2%
8%
EBIT (Operating Income) EBIT 15 15
160% 160%
1%
Net Profit 23 23
211% 211%
2%

In millions USD.

Don't miss a Thing! We will send you all news about Omnicell, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Omnicell, Inc. Stock News

Neutral
Business Wire
about 17 hours ago
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Appoints Baird Radford as Executive Vice President and Chief Financial Officer.
Neutral
Seeking Alpha
24 days ago
Omnicell, Inc. (NASDAQ:OMCL ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Kathleen Nemeth - Senior Vice President of Investor Relations Nchacha E. Etta - Executive VP & CFO Randall A.
Positive
Seeking Alpha
26 days ago
Omnicell's service business is rapidly growing, now 22% of revenue, outpacing industry trends and supporting long-term upside. My updated DCF analysis yields a price target of $57.46, representing 93% upside, with Wall Street consensus trailing behind. The primary risk is the pace of transition from product to service revenue, but a strong backlog mitigates margin and cash flow concerns.
More Omnicell, Inc. News

Company Profile

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence; platform and interoperability; central pharmacy dispensing; medication adherence; population health; and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Mountain View, CA.

Head office United States
CEO Randall Lipps
Employees 3,670
Founded 1992
Website www.omnicell.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today